Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information In appraisal
Process STA Standard
ID number 6340

Provisional Schedule

Committee meeting 05 November 2024
Expected publication 29 January 2025

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors Merck Sharp & Dohme (molnupiravir)
Others Department of Health and Social Care
  NHS England
Patient carer groups Cardiothoracic Transplant Patient Group
  Kidney Research UK
Professional groups Association of Cancer Physicians
  British Society for Immunology
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  UK Clinical Pharmacy Association
  UK Renal Pharmacy Group
Associated public health groups None
Comparator companies Gilead Sciences (remdesivir)
  GlaxoSmithKline (sotrovimab)
  Pfizer (nirmatrelvir plus ritonavir)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
12 April 2024 Invitation to participate
12 April 2024 As with previous technology appraisals of medicines for COVID-19, NICE is collaborating with the Scottish Medicines Consortium. See appendix 1 of the Final Scope for more details.
06 November 2023 - 04 December 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
06 September 2023 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual